Physician profile
Paul O Phelps
NPI 1003131657
$140,915.13
in general payments reported to CMS, 2019-2025
18 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $6,588 · 2021: $28K · 2022: $40K · 2023: $34K · 2024: $9,726 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $9,796 · Consulting Fee: $5,200 · Travel and Lodging: $3,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $28,943.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,525.00 |
| Food and Beverage | $9,796.48 |
| Consulting Fee | $5,200.00 |
| Travel and Lodging | $3,732.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $108,483.13 | 2019-2023 | Tepezza |
| Amgen INC. | $22,562.54 | 2024-2025 | Tepezza |
| Lumenis Be INC | $5,932.00 | 2025 | M22 |
| Oyster Point Pharma, INC. | $1,819.33 | 2022-2024 | |
| Alcon Vision LLC | $484.85 | 2022-2025 | Clareon, Hydrus Microstent |
| Glaukos Corporation | $410.19 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite, Idosetr |
| Biotissue Holdings INC. | $248.91 | 2021-2025 | |
| Allergan, INC. | $177.27 | 2019 | |
| Abbvie INC. | $170.55 | 2023-2024 | |
| Galderma Laboratories, L.P. | $170.23 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.76 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $109.72 | 2024-2025 | Xdemvy |
| Henry Schein, INC. | $77.67 | 2023 | |
| Revance Therapeutics, INC. | $49.82 | 2025 | Daxxify |
| Aerie Pharmaceuticals, INC. | $35.61 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumibird Medical INC. | $33.24 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.11 | 2025 | Clear+Brilliant |
| Hologic Sales and Service, LLC | $14.20 | 2025 | Coolseal Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.